Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Debt to Equity (2016 - 2023)

Historic Debt to Equity for Amicus Therapeutics (FOLD) over the last 15 years, with Q2 2023 value amounting to $0.12.

  • Amicus Therapeutics' Debt to Equity rose 491.56% to $0.12 in Q2 2023 from the same period last year, while for Jun 2023 it was $0.12, marking a year-over-year increase of 491.56%. This contributed to the annual value of $0.17 for FY2022, which is 18306.48% up from last year.
  • According to the latest figures from Q2 2023, Amicus Therapeutics' Debt to Equity is $0.12, which was up 491.56% from $0.12 recorded in Q1 2023.
  • In the past 5 years, Amicus Therapeutics' Debt to Equity registered a high of $0.41 during Q2 2020, and its lowest value of $0.03 during Q4 2020.
  • In the last 5 years, Amicus Therapeutics' Debt to Equity had a median value of $0.12 in 2023 and averaged $0.18.
  • In the last 5 years, Amicus Therapeutics' Debt to Equity surged by 150052.73% in 2019 and then crashed by 8995.34% in 2020.
  • Over the past 5 years, Amicus Therapeutics' Debt to Equity (Quarter) stood at $0.31 in 2019, then tumbled by 89.95% to $0.03 in 2020, then soared by 97.86% to $0.06 in 2021, then surged by 183.06% to $0.17 in 2022, then tumbled by 33.04% to $0.12 in 2023.
  • Its last three reported values are $0.12 in Q2 2023, $0.12 for Q1 2023, and $0.17 during Q4 2022.